Table 5– Summary of outcomes with standardised initial treatment and retreatment regimens (hypothetical cohorts of 1,000 new cases in each country start initial therapy with one of two standardised regimens)
CountryInitial regimenOutcomes after initial treatmentOutcomes after initial and retreatment#
Patients who relapse or fail nDeathsRelapse or fail, and survive with MDR-TBRelapse or fail, and survive with any other form of DR-TB
Dominican Republic2HRZE/6HE192125503
2HRZE/4HR106120510
Difference+865-13
Peru2HRZE/6HE12589212
2HRZE/4HR6385221
Difference624-11
Vietnam2HRZE/6HE18185165
2HRZE/4HR5973171
Difference12212-14
UR Tanzania2HRZE/6HE926751
2HRZE/4HR396360
Difference534-11
Nicaragua2HRZE/6HE1016741
2HRZE/4HR406350
Difference614-11
Gambia2HRZE/6HE866641
2HRZE/4HR386350
Difference483-11
Kenya2HRZE/6HE946311
2HRZE/4HR365920
Difference584-11
  • Data are rounded to whole numbers. MDR: multidrug-resistance; TB: tuberculosis; DR: drug resistance; 2HRZE: isoniazid, rifampin, pyrazinamide and ethambutol for 2 months; 6HE; isoniazid plus ethambutol for 6 months; 4HR: isoniazid plus rifampin for 4 months #: total number from original hypothetical cohort of 1,000 new cases; : not MDR-TB; +: difference is positive if outcome more frequent with 8-month regimen, and negative if outcome more frequent with 6-month regimen.